MOTS-c and Finasteride Interaction

Why This Interaction Question Matters

Men using finasteride for androgenetic alopecia or benign prostatic hyperplasia increasingly seek MOTS-c for its reported metabolic and longevity benefits. The absence of formal interaction studies creates uncertainty. Finasteride carries a well-characterized safety profile documented in its FDA prescribing information, but MOTS-c remains an investigational compound without regulatory approval. Clinicians must rely on mechanistic reasoning and pharmacological first principles to guide co-administration decisions.

The core question is whether MOTS-c alters finasteride's metabolism or amplifies its hormonal effects. Based on what is known about each compound's pharmacology, the answer appears to be no at the pharmacokinetic level, though pharmacodynamic considerations deserve attention in specific patient populations [1].

MOTS-c Pharmacology: How It Works

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is a 16-amino-acid peptide encoded within mitochondrial DNA. First characterized by Lee et al. in 2015 at the University of Southern California, MOTS-c activates AMPK (5' AMP-activated protein kinase) and regulates folate-methionine metabolism in skeletal muscle [2].

Unlike small-molecule drugs, MOTS-c is a peptide. It does not undergo hepatic phase I or phase II metabolism through cytochrome P450 enzymes. Peptides are degraded by circulating proteases and tissue peptidases, then cleared as amino acid fragments through standard protein catabolism. This means MOTS-c has no capacity to inhibit or induce CYP3A4, CYP2D6, or any other drug-metabolizing enzyme relevant to finasteride clearance.

MOTS-c also shows no known affinity for P-glycoprotein (P-gp) or organic anion transporting polypeptides (OATPs), the transporters that most commonly produce clinically significant drug interactions [3]. Its mechanism of action centers on AMPK activation, which influences glucose uptake, fatty acid oxidation, and mitochondrial biogenesis through pathways distinct from androgen receptor signaling.

Finasteride Pharmacology: Metabolism and Androgen Effects

Finasteride is a competitive inhibitor of type II 5-alpha reductase, the enzyme that converts testosterone to dihydrotestosterone (DHT). At 1 mg daily, it reduces scalp DHT by approximately 64% and serum DHT by roughly 70% [4]. The drug is metabolized primarily by CYP3A4 in the liver, with a terminal half-life of 5-6 hours in men aged 18-60.

Finasteride does not significantly inhibit or induce CYP enzymes at therapeutic doses. Its protein binding exceeds 90%, predominantly to albumin. The drug is not a substrate for P-glycoprotein efflux. These characteristics mean finasteride's pharmacokinetic profile is unlikely to be altered by co-administered peptides that bypass hepatic metabolism entirely.

The FDA label identifies no contraindicated drug combinations and lists no clinically significant pharmacokinetic interactions [5]. Population pharmacokinetic analyses from the Prostate Cancer Prevention Trial (N=18,882) confirmed stable finasteride exposure across patients taking multiple concomitant medications [6].

Pharmacokinetic Interaction Assessment

The pharmacokinetic interaction risk between MOTS-c and finasteride is negligible based on three independent lines of reasoning.

First, MOTS-c is a peptide cleared by proteolysis. It cannot compete with finasteride for CYP3A4 binding because it never enters the CYP metabolic pathway. Second, finasteride has no known effect on peptidase activity or AMPK signaling that would alter MOTS-c degradation kinetics. Third, neither compound is a clinically relevant P-gp substrate or inhibitor, eliminating transporter-mediated interactions from consideration.

No case reports, pharmacovigilance signals, or preclinical studies have identified a pharmacokinetic interaction between any mitochondrial-derived peptide and any 5-alpha reductase inhibitor [7]. This absence of signal, combined with mechanistic incompatibility, supports a classification of "no expected pharmacokinetic interaction."

Pharmacodynamic Considerations: The Androgen-Adjacent Question

While pharmacokinetic interaction risk is minimal, the pharmacodynamic picture requires more nuanced analysis. Both compounds influence biology that intersects with androgen metabolism, though through entirely different mechanisms.

MOTS-c activates AMPK, which in preclinical models has been shown to influence sex hormone-binding globulin (SHBG) production and may modulate testosterone bioavailability indirectly [8]. An AMPK-activated state tends to increase SHBG, which would reduce free testosterone and potentially reduce substrate availability for 5-alpha reductase. In theory, this could mildly augment finasteride's DHT-lowering effect.

Finasteride, by blocking DHT production, shifts the testosterone-to-DHT ratio. Testosterone levels may rise 10-15% during finasteride therapy as conversion to DHT is inhibited [4]. Whether MOTS-c-mediated AMPK activation meaningfully modifies this hormonal shift has not been studied directly.

The clinical significance of this theoretical pharmacodynamic overlap is likely minimal for most patients. The AMPK pathway's influence on SHBG is modest compared to the direct enzymatic blockade produced by finasteride. Patients should be aware of this theoretical interaction but should not expect clinically detectable amplification of either compound's effects.

Monitoring Recommendations for Co-Administration

Given the absence of formal interaction data, a conservative monitoring approach is appropriate for patients using both compounds under physician supervision.

Baseline labs before starting co-administration:

• Total and free testosterone
• DHT (dihydrotestosterone)
• PSA (if age-appropriate or clinically indicated)
• Fasting glucose and HbA1c
• Comprehensive metabolic panel
• SHBG

Follow-up at 8-12 weeks:

• Repeat DHT and total testosterone to confirm expected finasteride response
• Repeat fasting glucose (to assess MOTS-c metabolic effects)
• SHBG to evaluate any additive effects on androgen binding

If DHT suppression exceeds expected ranges (greater than 75-80% reduction from baseline) or if symptoms suggestive of excessive androgen suppression develop (sexual side effects, mood changes, fatigue), consider spacing the administration times or reducing the MOTS-c dose. The Endocrine Society's guidelines on androgen therapy monitoring provide a framework for interpreting these lab values in context [9].

Patient Populations Requiring Extra Caution

Three patient groups warrant heightened awareness when combining these compounds.

Men with baseline low testosterone. Finasteride can unmask symptomatic hypogonadism in men with borderline-low testosterone. If MOTS-c-mediated AMPK activation further increases SHBG and reduces free testosterone, the combined effect could push a borderline patient into the symptomatic range. Check free testosterone at baseline.

Patients using finasteride for BPH at 5 mg daily. The higher dose produces greater DHT suppression. Any additive pharmacodynamic effect from MOTS-c would be proportionally more relevant at this dose compared to the 1 mg hair-loss dose.

Individuals with insulin resistance or type 2 diabetes. MOTS-c's primary mechanism targets metabolic pathways. In patients already on metformin or other AMPK-activating therapies, adding MOTS-c introduces another AMPK stimulus. While not directly related to the finasteride interaction, the overall pharmacological burden should be assessed [10]. A study by Lee et al. demonstrated that MOTS-c improved insulin sensitivity in obese mice through AMPK-dependent glucose regulation [2].

Finasteride Side Effects: Does MOTS-c Change the Risk?

Finasteride's most discussed adverse effects are sexual: decreased libido, erectile dysfunction, and reduced ejaculate volume occur in 1.3-3.7% of men at the 1 mg dose according to the original Phase III trials [11]. The "post-finasteride syndrome" hypothesis suggests persistent sexual and neurological symptoms after discontinuation, though the NIH-funded study on this condition noted significant methodological limitations in existing reports [12].

No evidence suggests MOTS-c increases finasteride's sexual side effect risk. MOTS-c does not act on androgen receptors, does not inhibit neurosteroid synthesis, and does not cross the blood-brain barrier in meaningful concentrations based on available peptide pharmacokinetic data. The 5-alpha reductase enzyme also converts progesterone to allopregnanolone (a neurosteroid), and finasteride's inhibition of this pathway is hypothesized to contribute to mood-related side effects [13]. MOTS-c has no known interaction with this neurosteroid pathway.

If a patient experiences new sexual or mood symptoms after adding MOTS-c to an existing finasteride regimen, the most parsimonious explanation remains finasteride itself rather than a drug interaction. Standard clinical practice would be to discontinue one agent at a time to identify the causative compound.

What DDI Databases Say (and Don't Say)

Major drug interaction databases (Lexicomp, Micromedex, Clinical Pharmacology) do not contain entries for MOTS-c because it lacks FDA approval and has no NDA/BLA submission. This means no formal severity rating exists for this combination.

The absence of a database entry does not imply safety. It reflects insufficient regulatory review. Clinicians should document this combination in the patient's medication list and monitor as outlined above. As MOTS-c moves through clinical development (a Phase I trial NCT number has not been publicly registered as of this writing), formal interaction studies may eventually provide definitive data.

For finasteride specifically, Lexicomp lists no "X" (avoid combination) or "D" (consider modification) interactions with any peptide-class compound [14]. The drug's interaction profile is limited primarily to CYP3A4 inhibitors that can modestly increase finasteride exposure (e.g., ketoconazole), though even these are not considered clinically significant given finasteride's wide therapeutic index.

Timing and Practical Administration

No pharmacokinetic basis exists for separating MOTS-c and finasteride doses by time of day. Since they do not share metabolic pathways, simultaneous administration would not be expected to alter absorption or clearance of either compound.

Practical considerations:

• Finasteride is typically taken once daily at any consistent time
• MOTS-c is administered subcutaneously, commonly 2-3 times weekly in research protocols
• No food interaction exists for either compound that would necessitate coordinated timing
• If patients prefer to separate doses for psychological comfort, morning finasteride and evening MOTS-c injection (or vice versa) is reasonable but pharmacologically unnecessary

The Regulatory Reality of MOTS-c

MOTS-c is sold by compounding pharmacies and peptide suppliers, but it holds no FDA approval for any indication. The FDA's guidance on compounded peptides places unapproved peptides in a regulatory gray area [15]. Patients should understand that quality control, purity, and dosing accuracy vary between suppliers.

This regulatory status also means no manufacturer-sponsored interaction studies will exist unless MOTS-c enters formal pharmaceutical development. Clinicians prescribing or overseeing this combination accept responsibility for monitoring without the support of package-insert guidance.

Summary of Evidence and Clinical Decision Framework

The interaction between MOTS-c and finasteride can be assessed across four dimensions:

1. CYP450 competition: None. MOTS-c bypasses hepatic metabolism entirely.
2. Transporter interference: None. Neither compound is a clinically relevant P-gp substrate in this context.
3. Pharmacodynamic amplification: Theoretically possible but clinically minor. AMPK activation may slightly increase SHBG, marginally reducing free testosterone beyond what finasteride alone produces.
4. Safety signal in literature: Absent. No case reports, no pharmacovigilance flags, no preclinical red flags.

Prescribers can reasonably co-administer these compounds with standard monitoring. Baseline and 8-12 week follow-up labs (DHT, total/free testosterone, SHBG, metabolic panel) provide adequate safety surveillance for the theoretical pharmacodynamic interaction.